Efforts to understand autoimmunity have been pursued relentlessly for several decades. It has become apparent that the immune system evolved multiple mechanisms for controlling self-reactivity, and defects in one or more of these mechanisms can lead to a breakdown of tolerance. Among the multitude of lesions associated with disease, the most common seem to affect peripheral tolerance rather than central tolerance. The initial trigger for both systemic autoimmune disorders and organ-specific autoimmune disorders probably involves the recognition of self or foreign molecules, especially nucleic acids, by innate sensors. Such recognition, in turn, triggers inflammatory responses and the engagement of previously quiescent autoreactive T cells and B cells. Here we summarize the most prominent autoimmune pathways and identify key issues that require resolution for full understanding of pathogenic autoimmunity.
r e v i e w
The distinction between foreign and self by the immune system is not absolute, and under certain circumstances this system can be misdirected against the very entity it is intended to protect. Accordingly, aberrant responses to self have been linked to over 80 inflammatory disorders, collectively defined as 'autoimmune diseases' .
Autoreactivity ranges from a low 'physiological' level of selfreactivity essential for lymphocyte selection and immune-system homeostasis, to an intermediate level of autoimmunity that manifests as circulating autoantibodies and minor tissue infiltrates without clinical consequences, to pathogenic autoimmunity associated with immune-system-mediated organ injury. Autoimmune diseases have high prevalence (~7-9%) in the population, 'preferentially' afflict women, strike at the prime of life and cause considerable morbidity and mortality. On the basis of the extent of tissues involved, these are categorized as organ-specific diseases (for example, type I diabetes (T1D), multiple sclerosis, inflammatory bowel disease (IBD) and myasthenia gravis) and systemic diseases (for example, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's syndrome) and can be mediated by autoantibodies or cytotoxic T cells, but in all cases, helper T cells are required.
Most autoimmune diseases exhibit clinical heterogeneity, a polygenic nature and multifactorial contributions that often require both genetic factors and environmental factors 1 . While autoimmune diseases involve both innate immune responses and adaptive immune responses, the so-called 'autoinflammatory diseases' are associated with monogenic mutations that result in over-activation of the innate immune system without participation of the adaptive immune system 2 . Generally, genetic susceptibility results from the additive effects of several common risk variants, each with small effect sizes that alone are insufficient 3, 4 . These common variants probably persisted because of a survival advantage related to improved responses to infection and, not unexpectedly, they exhibit considerable variation among ethnic groups.
Several hundred loci associated with autoimmunity have been identified, including over 100 for RA, multiple sclerosis and IBD 3 . The overlapping of loci across diseases, frequently encompassing immune-system-related genes, suggests common mechanistic pathways, although the specific risk allele within a locus can differ depending on the disease. Among known genetic predisposing factors, certain major histocompatibility complex (MHC) haplotypes exert the strongest associations across most autoimmune diseases, but several other genes, including PTPN22, CTLA4, IL23R and TYK2, have frequently been implicated. Rare monogenic autoimmune diseases have also been identified, with mutations in AIRE, FOXP3, IFIH1, DNASE1, TREX1, C1Q or C4A, many of which have provided clues to understanding the pathogenesis of autoimmunity. For most loci, however, the actual risk alleles remain unknown because of linkage disequilibrium, extensive heterogeneity and incomplete sequence information. Moreover, most risk variants occur in poorly defined noncoding regions, which has challenged efforts to understand their effects on gene function.
The inefficiency of central tolerance
A key question in this field is how an immensely diverse antigenrecognition system, created mainly to detect and eliminate offending pathogens, avoids eliciting destructive anti-self responses. The main mechanisms of tolerance are exercised centrally: in the thymus, for T cells; and in the fetal liver and bone marrow, for B cells. However, is central tolerance infallible, and do escaping self-reactive cells contribute to the pathogenesis of autoimmune diseases?
The prevailing view has been that negative selection eliminates autoreactive T cells with high fidelity. However, early studies 5 and more-definitive subsequent studies have shown considerable 'leakage' in this process (Fig. 1) . For example, analyses with peptide-MHC tetramers have shown that the frequency and avidity of CD8 + T cells specific for diverse virus-derived peptides in healthy people not previously infected with those viruses are in the same range as that of T cells that recognize self peptides, while the frequency of CD8 + T cells specific for SMCY, an antigen encoded on the Y chromosome, is only two thirds lower in males than in females 6 . Incomplete deletion of SMCY-specific CD8 + T cells is also observed in male mice. Moreover, only ~60% deletion of Cre recombinase-specific CD4 + T cells is detected in the thymus and periphery of mice transgenic for ubiquitous expression of Cre and, impressively, no deletion is detected when Cre expression is restricted to the pancreas, lungs or intestine 7 . Therefore, it has been surmised that negative selection 'prunes' the repertoire with an efficiency proportional to the degree of self-antigen expression in the thymus but does not completely eliminate selfreactive T cells [6] [7] [8] .
A prime example of autoimmunity due to inadequate central deletion of autoreactive T cells is the syndrome APECED ('autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy'; also known as APS-1), a rare autosomal recessive disease caused by mutations of the gene encoding AIRE ('autoimmune regulator') 9, 10 . AIRE is a transcription regulator that activates super-enhancers and mediates the promiscuous expression of peripheral-tissue-restricted self molecules stochastically in individual medullary thymic epithelial cells 11 . AIRE also regulates genes encoding products involved in antigen presentation and the production of chemokines that modulate the density and function of thymic dendritic cells (DCs) as well as the development of regulatory T cells (T reg cells) 12 . Interestingly, B cells migrating into the thymus also express AIRE and contribute to selection of the T cell repertoire 13 . APECED is characterized by the T cell-mediated destruction of multiple endocrine organs, with considerable heterogeneity in phenotype, suggestive of contributions by additional predisposing genes and environmental factors. Studies have identified patients with dominant-negative monoallelic AIRE mutations associated with milder disease of later onset and lower penetrance but with a higher frequency in mixed populations 14, 15 . A syndrome similar to APECED develops in AIRE-deficient mice, and lower AIRE expression in heterozygous mice exacerbates T1D and collagen-induced arthritis. FEZF2 is another transcription factor that controls the thymic expression of tissue-restricted antigens that mostly do not overlap those affected by AIRE, and Fezf2 deficiency targeted to thymic epithelial cells also results in autoantibodies and inflammatory infiltrates in various organs 16 .
Like T cells, some autoreactive B cells escape central tolerance. Thus, large fractions of early immature B cells (~55-75%) in humans display autoreactivity, and this frequency progressively decreases to ~40% for bone-marrow immature B cells and peripheral transitional B cells and, finally, to ~20% for mature naive B cells 17, 18 . Those decreases occur at several checkpoints, starting with receptor editing and apoptosis early in ontogeny, followed by anergy induction before or immediately after emigration to the periphery 19 . Despite those checkpoints, polyspecific autoreactive B cells are present in the peripheral repertoire, and polyspecific natural autoantibodies are detectable in healthy humans and mice 20 . Natural autoantibodies are typically germline encoded, of the immunoglobulin M (IgM) isotype and non-pathogenic and can act as transporters for the disposal of cell debris or as a defense mechanism by preventing the dissemination of microbes to vital organs. It has been suggested, however, that polyspecific B cells might undergo somatic hypermutation and class switching to produce high-affinity IgG pathogenic autoantibodies. That proposal is supported by the high frequency of polyspecific B cell clones in patients with SLE, RA, T1D, Sjögren's syndrome or multiple sclerosis [18] [19] [20] , but it is unclear how such cells contribute to these distinct disease phenotypes. (Fig. 1) . Several inhibitory molecules (for example, CTLA-4, PD-1, LAG-3, TIM3, VISTA, TIGIT, FcγRIIb and certain Siglec proteins) are expressed on the surface of T cells and B cells to curtail excessive immune responses, both normal and anti-self. Deficiency in some of these molecules leads to autoimmunity, which provides strong evidence that autoreactive lymphocytes are present in the peripheral repertoire but are normally under control [21] [22] [23] [24] [25] [26] . Notably, blockade of these inhibitory molecules by specific antibodies has emerged as an effective anti-tumor approach, referred to as 'checkpoint immunotherapy' 27 . However, as expected, a wide range of immunerelated adverse events can occur due to unchecked autoreactivity.
T cell anergy, an acquired state of functional unresponsiveness, is a consequence of engagement of the T cell antigen receptor (TCR) in the absence of costimulatory signals 28 . Cells that have recently emigrated 30 . However, T cell anergy is not a long-lived state and can be reversed under inflammatory conditions. Approximately 5-7% of peripheral B cells seem to be in an anergic state, and transitional T3 B cells in the spleen may be anergic rather than being arrested at an intermediate developmental stage 31 . Because of the short half-life of anergic B cells (~5 days, in contrast to the 40-day half-life of follicular B cells), the proportion of newly emerging B cells that undergo anergy is estimated to be much higher, perhaps up to 50%. After being stimulated, anergic B cells show impaired activation, proliferation and antibody secretion due to reductions in both signal transduction and upregulation of basal intracellular Ca 2+ levels 32 . The anergic state is controlled by continuous low-level interaction with antigen and by a negative feedback circuitry mediated in part by the tyrosine kinase Lyn, the tyrosine phosphatase SHP-1 and the inositol phosphatase SHIP-1, and conditional deficiency in any of these molecules in B cells promotes systemic autoimmunity in mice 33, 34 . Anergic B cells, however, are not deleted and could potentially serve as a self-reactive reservoir. Indeed, reversion of IgM lo anergic B cells under inflammatory conditions has been suggested to contribute to autoimmune syndromes in humans with RA, SLE and T1D.
An issue not fully addressed is how the potential acquisition of self-reactivity by somatically hypermutated B cells is controlled. One potential mechanism is that autoreactive B cells might compete poorly for help from cognate T cells essential for the survival of B cells in germinal centers. In addition, B cells expressing a receptor with specificity for high-density membrane antigens might be deleted by a mechanism dependent on the cell-surface death receptor Fas (CD95).
Autoreactive T cells and B cells exported to the periphery can also remain quiescent due to ignorance of tissue-specific antigens sequestered behind anatomical barriers. This concept is especially applicable to tissues defined as 'immunologically privileged' sites, such as the eye, brain and testis. However, sequestration of peripheral tissue antigens can be broken by infectious agents or other causes of tissue damage; this leads to the engagement of 'ignorant' autoreactive cells and disease development. Such an event is contingent on several factors, including the nature and dose of the antigen, number of exposures, frequency of activated T cells and upregulation of the expression of MHC and costimulatory molecules in the affected tissues.
Exported self-reactive lymphocytes can be activated by several other mechanisms. Thus, the recognition of cryptic determinants not adequately presented in the thymus or bone marrow can be enhanced in the periphery under inflammatory conditions 35 . Another trigger might be the recognition of new self antigens generated by mutations, posttranslational and chemical modifications or the covalent cross-linking of distinct self peptides forming hybrid epitopes 36, 37 . Molecular mimicry by foreign antigens with sufficient sequence or conformational similarity to self antigens can also result in the activation of non-tolerant lymphocytes 38, 39 . Another mechanism by which microbes can promote autoimmunity is the capture of self antigens together with viral antigens by B cells, which leads to the presentation of self antigens, engagement of T cells and disease 40 . Examples of the mechanisms noted above have been reported for experimental models, but information on their involvement in the pathogenesis of human autoimmune diseases is limited.
The conundrum of strongly self-reactive T reg cells Several cell types exert a suppressive effect on innate and adaptive immune responses; among these, the CD4 + CD25 + FOXP3 + T reg cell subset is considered the most relevant 41, 42 . T reg cells develop in the thymus (thymic or natural T reg cells) but can also be generated in the periphery (induced T reg cells). The generation of thymic T reg cells is constrained by a niche defined by antigen presentation and the production of IL-2 by thymic DCs, as well as by feedback competition for IL-2 by mature T reg cells that recirculate to the thymus 43, 44 . T reg cells target all the main immunocyte subsets, and cell-to-cell contact is necessary for the suppressive effect, a fact documented by several approaches, including in vivo imaging showing clusters of T reg cells together with activated autoreactive T cells in secondary lymphoid tissues 45 . The suppression is mediated by inhibitory molecules (CTLA-4, IL-10, TGF-β and IL-35), cytolysis, interference with metabolic processes or modulation of the maturation and function of DCs. The metabolic signatures of human T reg cells differ from those of conventional T cells during activation and population expansion 46, 47 . Interestingly, T reg cells generated in the perinatal period persist and effectively inhibit autoimmunity throughout life 48 . The overall frequency of the polyclonal T reg cell population is approximately 5-15% of CD4 + T cells, but the ratio of antigenspecific T reg cells to effector T cells decreases during an ongoing immune response, presumably to improve anti-pathogen immunity 49 . T reg cells can also promote tissue repair in response to inflammatory factors released from damaged cells 50 and exert a regenerative effect on the central nervous system by mediating oligodendrocyte maturation and remyelination 51 . Such findings suggest an additional important function of T reg cells beyond suppression.
FOXP3 is essential for the development and function of T reg cells, and mutations in the gene encoding this transcription factor cause the scurfy phenotype in mice and IPEX syndrome ('immunodysregulation, polyendocrinopathy, enteropathy') in humans 41, 42 . Interestingly, activation of specific super-enhancers was shown to be required for Treg cell development 52 . T reg cells also exhibit high activity of PP2A, a serine-threonine phosphatase involved in controlling the pathway of the metabolic-checkpoint kinase complex mTORC1, and specific ablation of PP2A in T reg cells causes a severe multi-organ autoimmune disorder 53 .
Notably, thymus-derived T reg cells express TCRs with greater avidity for complexes of self peptide and MHC class II than that of TCRs expressed by conventional T cells. Accordingly, in a model of neuroinflammation, conventional T cells engineered to express myelin-oligodendrocyte-glycoprotein-specific TCRs derived from T reg cells exhibit higher functional avidity and are more pathogenic than natural conventional T cells, whereas T reg cells expressing myelin-oligodendrocyte-glycoprotein-specific TCRs from conventional T cells suppress disease less efficiently than do natural T reg cells 54 . The proposal of high self-reactivity of T reg cells is further supported by the finding that TCRs displayed by conventional T cells infiltrating target lesions in Aire −/− mice are frequently expressed by FOXP3 + T reg cells in Aire +/+ mice 55 . Thus, AIRE seems to promote both the deletion of high-affinity autoreactive T cells and the differentiation of intermediate-affinity clones into FOXP3 + T reg cells specific for peripheral self antigens.
The extent to which numerical or functional abnormalities in T reg cells contribute to human autoimmune disease has been difficult to ascertain due to considerable variation across studies in patient selection and undefined antigen specificities of T reg cells. Nevertheless, encouraging results have been reported in various experimental models of autoimmunity using T reg cell population expansion in vivo or adoptive transfer of T reg cells propagated in vitro 56, 57 . 58 , and some concerns have been raised because of the potential conversion of T reg cells into pathology-inducing effector cells under inflammatory conditions 59, 60 . Moreover, certain issues pertaining to the biology of T reg cells need further clarification, including the mechanisms by which these self-reactive cells escape central deletion, the molecular programs that confer the ability to inhibit autoimmune responses while allowing conventional responses, and the specific abnormalities that contribute to the pathogenesis of human autoimmune disease.
Nucleic-acid sensing as initial trigger of autoimmunity The study of autoimmune diseases has long centered on the adaptive immune system. However, the discovery that innate cells express a broad spectrum of sensors for foreign and self ligands has shifted focus to the innate immune system, the engagement of which precedes and ignites adaptive responses [61] [62] [63] . Thus, endosomal and cytosolic sensors that recognize foreign and self nucleic acids have been directly linked to the pathogenesis of various autoimmune diseases 64 . These endosomal sensors include TLR3 for double-stranded RNA, TLR7 and TLR8 for single-stranded RNA, and TLR9 for DNA, whereas the cytosolic sensors include the helicases RIG-I for uncapped 5′-triphosphate RNA and MDA5 for long double-stranded RNA, as well as multiple DNA sensors, of which the cGAS-cGAMP-STING pathway seems to be the most relevant 65, 66 (Fig. 2) . Responses by those sensors induce the production of type I interferons and pro-inflammatory cytokines (for example, IL-1, IL-6, IL-12 and TNF).
Retrospectively, the early findings of high concentrations of type I interferons in serum and dominance of type I interferoninducible transcripts in the periperal blood mononuclear cells of patients with lupus were the initial hints of a role for innate sensors in autoimmunity 67 . In addition, in vitro studies have shown that IgG from serum of individuals with lupus complexed with necrotic or apoptotic materials induce the production of type I interferons by plasmacytoid DCs (pDCs) and promote TLR9-dependent proliferation of B cells 68, 69 . Documentation of the chief role of type I interferons, specifically IFN-α, was provided by the diminished disease of lupus-predisposed mice lacking the interferon receptor IFNAR or treated with an IFNAR-blocking antibody, while IFN-β deficiency was ineffective in diminishing disease in such mice 70, 71 . Concurrent studies showed that deletion of Tlr9 reduced the titers of autoantibodies directed against DNA, but not overall disease, whereas deletion of Tlr7 reduced both the titers of autoantibodies directed against ribonucleoproteins and kidney disease 72 , which would suggest TLR7 is more pathogenic than TLR9, probably due to stronger signaling or greater availability of microparticles containing RNA derived from cell death. Interestingly, a duplication of Tlr7 due to translocation from the X chromosome to the Y chromosome enhances disease in male BXSB mice with lupus 73, 74 . Autoimmunity in Tlr7-transgenic mice is reported to be dependent on B cell autophagy 75 , and defects in non-canonical autophagy or in the engulfment and clearance of dying cells have been associated with lupus-like autoimmunity in mice 76 . Diminished disease is more evident in mice with deletion of both Tlr7 and Tlr9 (ref. 72 ) and is especially so in mice with mutation of the gene encoding the endoplasmic reticulum transmembrane protein UNC93B1, in which defective trafficking of TLRs from the endoplasmic reticulum to endolysosomes compromises responses to nucleic acids 77 . TLR responses to nucleic acids are also impaired by mutations in the genes encoding AP-3, BLOC-1 or BLOC-2, molecules critical for lysosome-related organelle trafficking and biogenesis in diverse cell types 78 , but the role of these molecules in autoimmunity has not yet been assessed. Notably, inactivation of Unc93b1 in mice with lupus diminishes not only the titers of anti-nuclear antibodies but also the broad spectrum of autoantibodies to several self antigens (such as cardiolipin, myeloperoxidase, β 2 -glycoprotein and erythrocytes), which indicates that nucleic acids are potent endogenous adjuvants for autoimmune responses to diverse nucleic-acid-associated self molecules 79 . Disease development requires the engagement of endosomal TLRs in both B cells and pDCs [79] [80] [81] [82] . Further studies of mice with lupus that have mutation of the gene encoding SLC15A4, an endosomal proton-histidine transporter required for TLR responses but not for the development of pDCs 78 , have shown that pDCs contribute to disease mainly through production of type I interferons and proinflammatory cytokines 80 . Expression of SLC15A4 in B cells is also crucial for TLR7-triggered production of type I interferons and autoantibodies in a pristaneinduced mouse model of lupus 83 . Surprisingly, in the MRL-lpr mouse model of lupus, DCs that are normally critical for adaptive immune responses are not required for the initial activation of T cells and B cells but instead are required for their population expansion and the Figure 2 Engagement of endosomal or cytosolic nucleic-acid sensors as central events in inflammatory responses. Nucleic-acid sensors are critical innate-immune-system receptors that reside either in endolysosomes or in the cytosol. After recognizing specific ligands, they initiate a signaling cascade that results in the activation of several transcription factors (IRF3, IRF7, NF-κB, AP-1) that promote cell activation and the production of type I interferons (IFN-α and IFN-β) and inflammatory cytokines. Two molecules in the endoplasmic reticulum (ER), GRP94 and PRAT4A, act in concert to ensure proper folding of TLR3, TLR7, TLR8 and TLR9 and their exit from the endoplasmic reticulum, while UNC93B1 mediates the transport of TLRs to endolysosomes, where ligand recognition takes place. Other proteins that participate in TLR trafficking and/or function are the adaptor AP-3, BLOC-1 and BLOC-2 ('biogenesis of lysosome organelle complex'), and the solute carrier SLC15A4 (a molecule known to transport protons (H + ), histidine (His) and selected peptides from endosomes to the cytosol). In the cytosol, RNA is sensed by the helicases RIG-I and MDA5, while DNA is sensed mainly by cyclic GMP-AMP synthase (cGAS). Engagement of cGAS leads to synthesis of the second messenger cGAMP, which interacts with STING (a stimulator of interferon-encoding genes) to promote inflammatory responses.
r e v i e w ensuing tissue damage, and kidney disease is dependent on signaling by the TLR adaptor MyD88 in B cells but not in DCs 84, 85 .
Further evidence of a central role for the recognition of self nucleic acids in systemic autoimmunity has been provided by the finding that gain-of-function mutation of Ifih1 (which encodes MDA5) promoted lupus-like disease in mice 86 . Moreover, spontaneous oligomerization of MAVS, the main signaling adaptor downstream of MDA5 and RIG-I, has been observed in peripheral blood lymphocytes of some patients with SLE and correlates with increased production of type I interferons and mitochondrial oxidative stress 87 . Notably, this phenomenon is diminished in sub-Saharan African patients expressing the MAVS-C79F variant with milder disease. Moreover, accumulation of extracellular or intracellular nucleic acids due to defects in DNase I (or its homolog DNASE1L3), DNase II or DNase III (TREX1) is associated in mice and humans with various forms of autoimmunity 64, 88 . The lupus-like autoimmunity of TREX1-mutant mice has been attributed to defective digestion of DNA derived from endogenous retroelements 89 , and a study has suggested that Ro60, a major autoantigen in SLE and Sjögren's syndrome, is associated with RNA that is derived from endogenous Alu retroelements and promotes TLR-dependent production of type I interferons 90 . Finally, neutrophil extracellular traps have been shown to induce endolysosomal TLR and type I interferon responses 91, 92 , and studies have indicated the involvement of oxidized mitochondrial DNA extruded from neutrophils activated by autoantibodies directed against ribonucleoproteins 93, 94 . Several accessory molecules (LL37, HMGB1 and RAGE) and uptake of immunocomplexes by the receptor FcγR have been identified as major mechanisms for the access of self nucleic acids to endolysosomal sensors 64 . Notably, in addition to IgG autoantibodies, DNA-reactive IgE can also enhance type I interferon responses by pDCs and contribute to the immunopathology of SLE 95 .
Overall, a unified concept has emerged in which autoimmune pathological processes are initiated by the engagement of innate sensors by nucleic acids (Fig. 3) . Most of the examples cited relate to SLE, but this mechanism seems to be applicable to a broad spectrum of systemic and organ-specific autoimmune diseases (for example, RA, Sjögren's syndrome, polyomyositis-dermatomyositis, psoriasis, T1D, autoimmune thyroiditis and neuromyelitis optica) 64 . Self nucleic acids acting under sterile conditions are frequently the initial trigger, but microbial nucleic acids alone or together with self nucleic acids from damaged tissues might also contribute to the initiation of disease. Thus, the sensing of nucleic acids, an essential evolutionarily acquired mechanism that acts to protect an organism against pathogens, is under certain circumstances a major mediator of pathogenic autoimmunity.
The hidden microbial 'self' and autoimmunity The microbiota, an ecosystem of microorganisms residing in mucosal surfaces and the skin in mutually beneficial coexistence with the host, influences numerous physiological processes, including the evolution of organisms, longevity, metabolism and immune-system development and function. However, a large body of publications has now revealed that disturbances in this ecosystem, referred to as 'dysbiosis' , can lead to a plethora of pathological processes, including autoimmune diseases that affect not only the gut, the largest niche for the microbiota, but also several distant organs 96, 97 (Fig. 4) .
IBDs, which encompass Crohn's disease and ulcerative colitis, were the first to be associated with dysbiosis. Initial studies showed substantial taxonomic shifts in gut microbiota of people with these syndromes, including decreases in beneficial subtypes of Clostridia and Bacteroides fragilis 98 . The fermentation of dietary fibers by Clostridia clusters IV, XIVa and XVIII produces short-chain fatty acids, particularly butyrate, which exert substantial anti-inflammatory effects, promote the generation of peripheral T reg cells and are key nutrients for colonocytes [99] [100] [101] [102] . Moreover, subtypes of B. fragilis and certain other intestinal bacteria produce capsular polysaccharide A, which provides immunological protection through the induction of IL-10-producing T reg cells, and administration of B. fragilis or even polysaccharide A alone corrects immunological defects in germ-free mice and has protective effects in models of colitis 103, 104 . Further, the intestinal tissues of patients with IBD often show downregulation of the aryl hydrocarbon receptor, which, in response to bacteria-derived indole metabolites, induces the production of IL-22 by group 3 innate lymphoid cells 105 . That effect promotes the expression of antimicrobial proteins by epithelial cells, limits the expansion of commensal segmented filamentous bacteria and reduces activation of the inflammatory T H 17 subset of helper T cells in mice 106, 107 . Patients with IBD also have a greater abundance of Escherichia coli and other bacterial strains with epithelium-adhesive properties that promote inflammatory T H 17 responses, and mutations in the gene encoding the intracellular bacterial sensor Nod2 linked to Crohn's disease are sometimes associated with compositional shifts to inflammationpromoting gut microbiota 96 .
Complex disturbances in the microbiota have been linked to the pathogenesis of T1D in the non-obese diabetic mouse strain and humans 108 . Interestingly, longitudinal studies of children have shown reductions in microbiota diversity and butyrate-producing bacteria r e v i e w in the time period between seroconversion to autoantibody positivity and diagnosis, although the bacterial diversity of autoantibodypositive people without overt disease showed no significant difference relative to that of healthy control subjects 108 . Another study has shown that the dominant gut microbial taxa of infants from countries in which early-onset T1D is common produce an immunoinhibitory lipopolysaccharide, whereas the dominant bacteria of infants from regions in which early-onset T1D is less prevalent produce an immunostimulatory lipopolysaccharide 109 . Notably, immunostimulatory lipopolysaccharide delays the onset and diminishes the incidence of diabetes in mice of the non-obese diabetic strain, but injection of immunoinhibitory lipopolysaccharide does not. Such results suggest that early stimulation of the innate immune system might diminish the predisposition to autoimmune diseases and provide a potential mechanistic explanation for the 'hygiene hypothesis' of autoimmunity. Dysbiosis has also been linked to diseases at sites distant from the gut, including a spectrum of neurological disorders, such as anxiety, stress, migraines and depression, as well as neurodegenerative and neuroinflammatory diseases. In the context of neuroinflammation, the main supporting evidence of such an association is that germ-free mice are refractory to experimental autoimmune encephalomyelitis, but susceptibility to this disease is restored by colonization with T H 17-cell-promoting segmented filamentous bacteria. In contrast, B. fragilis expressing polysaccharide A or other bacteria that metabolize dietary fiber to short-chain fatty acids or that metabolize tryptophan to agonists of the aryl hydrocarbon receptor diminish neuroinflammation in a model of experimental autoimmune encephalomyelitis 110, 111 . For multiple sclerosis, studies are limited, and although changes in certain gut bacteria species have been associated with disease, there is lack of consensus for the specific bacteria linked to this disease 112 .
Microbiota disturbances also reportedly affect arthritis in mice and humans. For example, gut microbiota is required for the development of arthritis in the K/BxN, SKG, Il1rn −/− and HLA-B27 models, while dysbiosis has been reported in humans with RA, reactive arthritis, psoriatic arthritis or spondyloarthritis 113 . In RA, contributions by oral and gut microbiota, particularly Porphyromonas gingivalis and Prevotella copri, have been suggested 113 . Interestingly, P. gingivalis expresses peptidylarginine deiminase and the cysteine-like proteases gingipains that can promote the citrullination of peptidylarginine deiminase and self antigens and the induction of antibodies to citrullinated peptides that are almost pathognomonic for RA 114 . However, additional studies have not confirmed enrichment for P. copri and have detected P. gingivalis and antibodies to this microbe in people who do not have RA but have periodontal disease 115 . Moreover, another periodontitis-associated microbe (Aggregatibacter actinomycetemcomitans) can contribute to the production of antibodies to citrullinated peptides in RA by triggering dysregulated activation of citrullinating enzymes in neutrophils and the release of citrullinated self antigens 116 .
The findings as a whole provide compelling evidence for the astonishing ways dysbiosis can affect a wide spectrum of autoimmune diseases. The strongest evidence is derived from studies of experimental models, while findings for humans are circumstantial and are largely based on often discordant surveys of microbiota ecosystems, and cause-and-effect relationships have not been clearly established. Moreover, there are several limitations and pitfalls in interpreting changes in the microbiota of humans that should be considered before patient-specific data are integrated with a given disease. This is particularly relevant, since the gut microbiota is highly dynamic, exhibits daily cyclical fluctuations related to circadian rhythms and variable bacteria growth rates 117, 118 , and is affected by diet and medications. In addition, the mechanisms by which dysbiosis contributes to autoimmune diseases distant from the gut need more detailed characterization. Nonetheless, despite such caveats, dietary and other interventions to correct dysbiosis have been advocated as a new therapeutic approach for a broad spectrum of disorders.
Non-coding RNAs as modulators of autoimmunity
Estimates indicate that only ~2% of the mammalian genome encodes proteins, while the vast majority (75-90%) is transcribed as noncoding RNA, including microRNAs (miRNAs) 18-23 nucleotides in length and long non-coding RNAs (lncRNAs) of 200 nucleotides or more, with substantial effects on both the innate and the adaptive immune systems. Functionally, miRNAs bind to their mRNA targets and mediate gene silencing mostly by translational repression and transcript degradation 119 , while lncRNAs are transcribed in a cellspecific manner and act biochemically by interacting with proteins, DNA or RNA 120, 121 (Fig. 4) . Figure 4 The multiple pathways to autoimmunity. We posit that autoimmunity might result from disturbances in multiple processes acting singly or in combination. Tissue damage under sterile conditions or due to infection can lead to the availability of nucleic acids and other damageassociated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), the presentation of self antigens to non-tolerant lymphocytes, and the induction of inflammatory responses. Dysbiosis of the microbiota can result in the displacement of beneficial commensals, a decrease in the abundance of several anti-inflammatory factors (shortchain fatty acids (SCFA), aryl hydrocarbon receptor ligands (AHR-L) and polysaccharide A (PSA)), expansion of adherent bacterial populations (for example, segmented filamentous bacteria (SFB) in mice), damage of the mucosal-epithelial barrier, and translocation of bacteria and inflammatory products to mesenteric lymph nodes. Such effects lead to the engagement of TLRs and other innate sensors, the production of inflammatory cytokines, the contraction of T reg cell populations, the expansion of T H 17 cell and other effector-cell populations, and the production of autoantibodies, which results in organ-specific or systemic autoimmune disease. Additional factors that might contribute to autoimmunity include abnormalities in non-coding regulatory RNAs, sex-associated hormonal effects and incomplete X-chromosome inactivation. These processes require a predisposing genetic background for development of the pathogenic phenotype. Trp, tryptophan; IFN-I, type I interferons; T FH cells, follicular helper T cells; T eff , effector T cell.
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Published evidence has linked diverse miRNAs to inflammatory and autoimmune processes. For example, transgenic overexpression of the polycistronic miRNA cluster miR-17~92 in mice causes lymphoproliferation and lupus-like autoimmunity characterized by the accumulation of follicular helper T cells and reduces expression of the tumorsuppressor phosphatase PTEN and the anti-apoptotic molecule Bim 122 . Further studies of specific members of the miR-17~92 cluster have shown that miR-19 suppresses the expression of PTEN and has a key role in regulating central B cell tolerance, while miR-17 controls early B cell development 123 . Defects in B cell tolerance have also been noted in irradiated mice reconstituted with hematopoietic stem cells transduced with a miR-148a vector, and overexpression of this miRNA accelerates autoimmunity in a mouse model of lupus 124 . Deletion of miR181a, miR185 or Dicer (a molecule required for the biogenesis of miRNA) is also reported to promote autoimmunity in mouse models, while expression of miR146a in T reg cells is required for the inhibition of pathogenic T H 1 responses and maintenance of immunotolerance 119 . The translation of such findings to human autoimmune diseases is at an early stage, but increases or decreases in certain miRNAs and lncRNAs have been detected in such diseases and sometimes correlate with disease severity [125] [126] [127] .
Sex bias in autoimmunity
It has long been recognized that most autoimmune diseases exhibit considerable sex dimorphism, with a higher incidence in females 128 . Two main factors are thought to contribute to this dimorphism: gonadal hormones and direct X-chromosome effects (Fig. 4) . The contribution of sex hormones has been suggested by the observations that sex bias is more evident after puberty and that estrogens enhance immune responses and autoimmunity in lupus-predisposed mice, while androgens suppress this. Female hormones exert broad effects on the expression of multiple genes encoding immunologically relevant molecules, including inflammatory cytokines and TLR signaling molecules 129, 130 . Estrogens also interfere with B cell tolerance 131 , and T cell tolerance might also be affected, since AIRE expression in thymic epithelium is reported to be downregulated by estrogens and upregulated by androgens 132, 133 . Sex hormones and the microbiota also influence each other, and sex differences in microbiota composition may also contribute to sex bias in autoimmunity 134, 135 .
The gonad-independent role of the X chromosome was first demonstrated in a model of XX and XY mice bearing either ovaries or testes, in which susceptibility to experimental autoimmune encephalomyelitis and pristane-induced lupus was dependent on XX status whether the mice developed as female or male 136 . Three interconnected mechanisms have been proposed to explain direct contributions of the X chromosome to autoimmunity: escape from X-chromosome inactivation, loss of mosaicism, and aneuploidy. X-chromosome inactivation is a major epigenetic event that ensures that only one of the two X chromosomes is expressed in female cells, as a mechanism to equalize gene dosage between females and males. Because this process is random, either the maternal X chromosome or the paternal X chromosome is inactivated in each cell, which results in mosaicism in females. X-chromosome inactivation is variable and incomplete, with up to ~15% of genes (~200 genes) expressed by both X chromosomes in humans, which results in higher expression of such genes in females than in males 137, 138 . Interestingly, the degree of escape from X-chromosome inactivation varies among tissues, people and ethnic groups 139, 140 . Depending on the nature of the genes that escape inactivation, the potential effect on autoimmunity can be detrimental if the genes that escape encode products involved in activation of the immune system (for example, DDX3X, BTK and TLR7), or they can be beneficial if the products are involved in immunoregulation (for example, FOXP3). The effect of incomplete X-chromosome inactivation can be amplified in females with loss of mosaicism in certain tissues or cell populations, as well as in people with X aneuploidy, such as patients with Kleinefelter syndrome, in whom all but one of the X chromosomes are inactivated 141 . Because the female bias is not uniform in all autoimmune diseases, it will be of interest to determine the underlying pathogenic processes that influence this bias and to elucidate why males seem to require a greater cumulative genetic risk for disease development 142 .
Concluding remarks
This Review has summarized the main triggers and pathways involved in the pathogenesis of autoimmune disease. Each is based on a distinct mechanistic principle, but probably more than one pathway contributes to a given disease. These pathways have been well established in experimental models, but evidence of involvement in human disorders is frequently tentative. Nonetheless, the data available highlight the outstanding progress made thus far in the quest to define the pathogenesis of these highly complex and heterogeneous syndromes, and clearly novel diagnostic and therapeutic approaches will be forthcoming. The application of new technologies might even allow the specific elimination of autoreactive cells without broad suppression of the entire immune system, as is currently the practice. An indication of the feasibility of antigen-specific therapy in autoimmunity has been provided by studies showing depletion of autoantigen-specific B cells through the use of cytotoxic T cells expressing chimeric antigen receptors 143 , and the population expansion of autoantigen-specific T reg cells (for passive transfer) via nanoparticles displaying disease-relevant self peptide-MHC complexes 144 . Furthermore, as genetic predisposition is a prerequisite for most autoimmune diseases, it is expected that advances in defining the role of genetic variations in these syndromes will be transformative in approaches to diagnosis and treatment.
